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New therapies for TC 
DE ~~I~et molecular defects 
THYROIDECTOMY and :he dissection of these over diagnosed cases skews the sta-
the central neck compartment is the ini- tis tics by lumping clinically significant 
tial step in treatment of thyroid cancer cases in apparently harmless cases . . 
(TC) in a majority of cases. A thyroid-pre- TC is incredibly common with autopsy 
serving ' operation may be applied in studies of people dying from other causes ' 
cases, when TC exhibits low biological ag- showing that more than one-third of 
gressiveness (eg well-differentiated can- older 'adults technically have TC, which is 
cer, no evidence of lymph node causing no harm. It is easy to detect nod-
metastases, low MIB-1 index, no major ge- ules that might be cancerous, simply by 
,netic alterations like BRAF mutations. feeling the throat, which contributes to 
RET/PTC rearrangements, p53 mutations the level of diagriosis. Benign (non-can-
etc) in patients younger. than 45 years. If cerous) nodules frequently co-exist with 
the diagnosis of well-differentiated TC TC, sometimes, it is a benign nodule that 
(eg papillary TC) is established or sus-. discovered. but surgery uncovers an inci-
pected by FNA the surgery is indicated, dental small TC Increasingly, small thy-
whereas watchful waiting surgery is not roid nodules are discovered as incidental 
recommended in any evidence-based findings on imaging (CT scan, MRl, ultra-
guidelines. Watchful waiting reduces sound) performed for another purpose; 
over-diagnosis and overtreatment of TC very ofthese people with accidentally dis-
among old patients. . covered, symptoms-free TCs will ever 
Radioactive iodine-131 is used in pa:- have any symptoms and treatment in 
tients with papillary or follicular TC for such patients has the potential to cause 
ablation of residual thyroid tissue after harm to them, not to help them. 
surgery and for treatment of TC Patients TC is three times more common in 
with medullary, anaplastic and most women that in men, but according to Eu-
Hurthle cell cancers do not benefit from ropean statistiCs, the overall relative 5- -
this therapy. External radiation may be year survival rate for TC is 85 per cent or 
used when it is unresectable, when it oc- females and 74 per cent for males. There 
curs after resection or to relieve p~infrom are challenges with decision making and 
bone metastases. Sorafenib and sunitinib, prognostication in TC While there isgen-
approved for other Indications show pos- eral agreement that stage 1 or stage 11 
itive promise for TC are being used for papillary, follicular or modularly cancer 
some patients who do not qualify for clin- . have a: good prognosis, it is not possible 
ical trjals. Numerous agents are in phase- when evaluating a small TC to determine 
11 clinical trials and XI, 1984.184 has which one will grow and metastasize and 
started a phase III trial. which will not. As a result, once a diagno-
sis ofTC has been established (most com-
,monly by fine needle aspiration), it is 
likely that a total thyroidectomy will be 
performed. This drive to earlier diagnosis 
has also manifest itself on the European 
continent by use of serum calcitonin 
measurement in patients with goiter to 
identify patients with early abnormalities 
of the parafolicullar or calcitonin-pro-
ducing cells within the thyroid gland. As 
multiple studies have demonstrated the 
finding of an elevated serum calcitonin is 
associated with finding of a medullary 
thyroid carcinoma in as high as 20 per 
cent of cases .. 
Outcome-prognosis 
Disease outcome or prognosis of TC is 
related to the type of cancer and the' stage 
. at the time of diagnosis. For the most 
common form ofTC, papillary, the overall 
prognosis is excellent. Indeed, the in-
creased incidence of papillary ' thyroid 
carcinoma in the recent years is likely to 
increased and earlier diagnosis. The argu-
ment against early diagnosis and treat-
ment is based on the logic that many 
small thyroid cancers (mostly papillary) 
will not grow or metastasize (that is, Will 
never cause any symptoms, illnesses or 
death for the patient, even jf nothing is . 
ever done about the cancer). Including 
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.sance in TC treatment. The identification of 
some molecular or DNA abnormalities for 
TC has led to the development of therapies 
that target molecular defects. The first of 
these agents to negotiate the approval 
process is vandetanib, a tyrosine kinase in-
. hibitor that targets the RET proto-onco-
gene 2 subtypes of the vascular endothelial 
growth tactor receptor. Prognosis is better 
in younger people than older ones. 
Thyroid diseases 
Clinically related thyroid diseases in-
clude poorly differentiated TC, thyroid 
lymphoma, thyroid neoplasm and thy-
roid nodule . 
Poorly differentiated thyroid cancer 
(PDTC) is a malignant neoplasm of fqllic-
ular cell origin showing intermediate his-
tological patterns between differentiated 
and undifferentiated TC Diagnosis of 
PDTC is mainly on histological features, 
. (a) presence of small cells with round nu-
clei and scat cytoplasm with diffuse solid 
patterns, (b) round or oval nests (insulae) 
or trabeculae, (c) solid growth and pres-
ence of micro follicles, some of which 
contain dense colloid ( d) extra thyroidal 
extension and blood vessel invasion, (e) 
foci of necrosis, and (f) larger than 5 cm 
in greatest diameter at diagnosis. Clini-
cally PDTC affects predominantly females 
about 55 years of age, and both local and 
distant, lung, bone and brain is affected. 
Thyroid lymphoma is a rare malignant 
tumour constituting 1 - 2 per cent of all 
thyroid malignancies and less than 2 per 
cent of lymphomas. Thyroid lymphomas 
are classified as non-Hodgkin's B-celllym-
phomas in a majority of cases, although 
Hodgkin's lymphoma of the thyrOid has 
also been identified. Clinical manifesta-
tions are similar to other thyroid lesions, . 
" . 
thyroid lymphoma affects predominantly 
female over 70 years of age with a history 
of Hashimoto's thyroiditis. Thus, 
Hashimoto thyroiditis is considering as 
risk factor for thyroid lymphoma develop-
ment. The thyroid lymphoma manifests as 
rapidly enlarging neck mass .causing res-
piratory difficulty. On physical examina-
tion, patients usually . exhibit a firm 
thyroid and lymphadenopathy. Fre-
quently associated symptoms are painless 
neck mass, hoarseness, dysphagia and 
signs of tracheal compression. 
Thyroid lymphoma shows a diagnostic 
and therapeutic challenge in many cases, 
because some manifestation patterns are 
similar to (Anaplastic thyroid carci-
noma). Performance of FNAB has helped 
to distinguish these two entities preoper-
atively. The combined modality therapy is 
the most common approach for the ini-
tial treatment of thyroid lymphomas. The · 
CHOP regimen( cyclophosphamide, dox-
orubicin, vincristine and prednisone) has 
been shown high effectiveness for many 
types of lymphoma. However, it is sug-
gested to perform radi.ation therapy only 
for MALT (mucosal-associated lymphoid 
tissue) resulting in a 96 per cent complete 
response, with only 30 per cent relapse 
rate. Surgical treatment might be per-
formed for patieIlts with thyroid lym-
phoma in addition to chemotherapy and 
radiation, particularly for MALT lym-. 
phomas. Staging of lymphoma from . 
stage IE - to 4E depending on the location 
of the lymphoma. Outcome (prognosis) 
of lymphoma patients are advance age of ' 
the tumour, large size (> lOcm) as well as 
spreading to mediastinum. The overall 
survival for primary thyroid lymphoma is 
50 -70 per cent, ranging from 80 per cent 
in stage IE to less than 36 per cent in stage 
Thyroid nodules can be discovered 
via imaging, using an ultrasound. 
lIE and 4E in 5 years .. 
Thyroid neoplasm is a neoplasm ortu-
mout of the thYroid. It can be benign tu-
mour such as thyroid adenoma, or it can 
be a malignant neoplasm (thyroid can-
cer), such a papillary,follicular, medullary 
or anaplastic thyroid cancer. Most pa-
tients are 25-65 years of age when first di-
. agnosed. Women are more affected than 
men. In' 2010, in US 44, 670 reporte3d 
cases and 1, 690 deaths. Of all thyroid nod-
ules discovered only 5 per cent are cancer-
ous arid under J per cent of those result in 
fatalities. 
DiagnosiS with blood tests, an ultra-
sound and nuclear scan. Patients are also 
tested for hyperthyroidism and hypothy-
roidism, two conditions that often arise 
from an abnormally functioning thyroid 
gland. Thyroid adenoma is benign neo-
plasm of the thyroid. Thyroid nodules are 
very common and round 80 per cent of 
adults will have at least one by the time 
they reach 70 years of age: 
Approximately 90 - 95 per cent of all 
nodules are found to be benign. Nearly 
. 80 per cent of thyroid cancer is papillary 
and about 15 percent is follicular, both 
types grow slowly and can be cured if 
caught early. MedullaryTC makes about 3 
per cent of this cancer. . 
Anaplastic is the most deadly and 
makes up 2 per cent. · This type grows 
quickly and is hard to control. Other thy-
roid malignancies inClude thyroid lym-
phoma, various types of thyroid sarcoma, 
smooth muscle tumours, teratoma, squa-
mous cell thyroid carcinoma and other 
rare types of tumours. 
This series on thyroid cancer 
concludes next week, with a look ' 
at treatments for the disease. 
